Show simple item record

dc.creatorZečević, Mira
dc.creatorSavić, G
dc.creatorŽivanović, L
dc.date.accessioned2019-09-02T11:05:38Z
dc.date.available2019-09-02T11:05:38Z
dc.date.issued2006
dc.identifier.issn0003-2719
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/775
dc.description.abstractA reversed-phase liquid chromatography method has been developed for the separation of valdecoxib and impurity SC-77852. The best results were achieved using a mobile phase-methanol: 1% water solution TEA (52 : 48 v/v), pH 7.35 (adjusted with 85% orthophosphoric acid), column temperature 24 degrees C. Separation was carried out on XTerra (TM) RP18 (150mm x 4,6 mm), particle size 5 mu m, flow rate 1ml/min, using detection on 220 nm. The method was statistically validated for its selectivity, linearity, precision (repeatability), and robustness. Quantitation and detection limits were determined for both valdecoxib and SC-77852. Method robustness was further evaluated by performing full factorial design experiment. Validated method was used for assay of valdecoxib and SC-77852 in Bextra (R) film-coated tablets.en
dc.publisherTaylor & Francis Inc, Philadelphia
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/142071/RS//
dc.rightsrestrictedAccess
dc.sourceAnalytical Letters
dc.subjectvaldecoxiben
dc.subjectrobustnessen
dc.subjectexperimental designen
dc.subjectRP HPLCen
dc.subjectSC-77852en
dc.titleDevelopment and validation of liquid chromatography method for the separation of valdecoxib and its SC-77852 impurityen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractЖивановић, Л; Савић, Г; Зечевић, Мира;
dc.citation.volume39
dc.citation.issue9
dc.citation.spage1875
dc.citation.epage1890
dc.citation.other39(9): 1875-1890
dc.citation.rankM23
dc.identifier.wos000238565900009
dc.identifier.doi10.1080/00032710600721605
dc.identifier.scopus2-s2.0-33745626824
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record